Drew Pardoll on neoadjuvant nivolumab in stage 1-3 NSCLC
The neoadjuvant PD-1 blockade in resectable lung cancer led to major pathological responses in 45 percent of the patients enrolled in a clinical trial.
Drew Pardoll, MD, PhD, director of Bloomberg~Kimmel Institute for Cancer Immunotherapy and director of Cancer Immunology at Johns Hopkins School talks about the data from a clinical trial in which nivolumab was given prior to resection in stage 1-3 NSCLC. According to the results, the administration of neoadjuvant nivolumab in this setting is safe and resulted in major pathological responses in 45% of the patients.
More from this topic: